Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed

The Lancet

Volumn 376, Issue 9737, 2010, Pages 285-301

  Degenhardt, Louisa ^a   Mathers, Bradley ^a   Vickerman, Peter ^b,d   Rhodes, Tim ^b,e   Latkin, Carl ^c   Hickman, Matt ^d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF BRISTOL   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COCAINE; DIAMORPHINE; METHAMPHETAMINE; NALTREXONE; OPIATE;

BEHAVIOR THERAPY; CD4 LYMPHOCYTE COUNT; COCHRANE LIBRARY; COST EFFECTIVENESS ANALYSIS; DRUG DEPENDENCE; DRUG DETOXIFICATION; ECONOMIC ASPECT; ENVIRONMENTAL FACTOR; EPIDEMIC; HEROIN DEPENDENCE; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INTRAVENOUS DRUG ABUSE; NEEDLE; PATIENT COUNSELING; POLICY; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; SCALE UP; SEXUAL TRANSMISSION; SEXUALITY; SOCIAL CHANGE; SOCIAL ENVIRONMENT; SUBSTITUTION THERAPY; SYRINGE; VIRUS LOAD; VIRUS TRANSMISSION;

EID: 77955057113     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60742-8     Document Type: Review

References (150)

1. UNAIDS. 2008 report on the global AIDS epidemic. August, 2008. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008-Global-report.asp (accessed May 13, 2010).
2. Mathers BM, Degenhardt L, Ali H, et al, for the 2009 Reference Group to the UN on HIV and Injecting Drug Use. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375: 1014-1028.
3. Mathers BM, Degenhardt L, Phillips B, et al, for the 2007 Reference Group to the UN on HIV and Injecting Drug Use. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet 2008; 372: 1733-1745.
4. Rachlis B, Brouwer KC, Mills EJ, Hayes M, Kerr T, Hogg RS. Migration and transmission of blood-borne infections among injection drug users: understanding the epidemiologic bridge. Drug Alcohol Depend 2007; 90: 107-119.
5. Baggaley RF, Boily MC, White RG, Alary M. Risk of HIV-1 transmission for parenteral exposure and blood transfusion: a systematic review and meta-analysis. AIDS 2006; 20: 805-812.
6. Marincovich B, Castilla J, Del Romero J, et al. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003; 79: 160-162.
7. Pedraza M-A, del Romero J, Roldán F, et al. Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999; 21: 120-125.
8. Boily M-C, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9: 118-129.
9. Vitinghoff E, Douglas J, Judon F, McKiman D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol 1999; 150: 306-311.
10. Strathdee SA, Hallett TB, Bobrova N, et al. HIV and risk environment for injecting drug users: the past, present, and future. Lancet 2010; published online July 20. DOI:10.1016/S0140- 6736(10)60743-X.
11. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy 2009; 20: 193-201.
12. Denison JA, O'Reilly KR, Schmid GP, Kennedy CE, Sweat MD. HIV voluntary counseling and testing and behavioral risk reduction in developing countries: a meta-analysis, 1990-2005. AIDS Behav 2008; 12: 363-373.
13. Lyles CM, Kay LS, Crepaz N, et al, for the HIV/AIDS Prevention Research Synthesis Team. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000-2004. Am J Public Health 2007: 97: 133-143.
14. Elwy AR, Hart GJ, Hawkes S, Petticrew M. Effectiveness of interventions to prevent sexually transmitted infections and human immunodeficiency virus in heterosexual men: a systematic review. Arch Intern Med 2002; 162: 1818-1830.
15. Semaan S, Des Jarlais DC, Sogolow E, et al. A meta-analysis of the effect of HIV prevention interventions on the sex behaviors of drug users in the United States. J Acquir Immune Defic Syndr 2002; 30 (suppl 1): S73-93.
16. Crepaz N, Lyles CM, Wolitski RJ, et al. Do prevention interventions reduce HIV risk behaviours among people living with HIV? A meta-analytic review of controlled trials. AIDS 2006: 20: 143-157.
17. Stanton MD, Shadish WR. Outcome, attrition, and family-couples treatment for drug abuse: a meta-analysis and review of the controlled, comparative studies. Psychol Bull 1997; 122: 170-191.
18. El-Bassel N, Witte SS, Gilbert L, et al. Long-term effects of an HIV/STI sexual risk reduction intervention for heterosexual couples. AIDS Behav 2005; 9: 1-13.
19. Medley A, Kennedy C, O'Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS Educ Prev 2009; 21: 181-206.
20. Tilson H, Aramrattana A, Bozzette S. Preventing HIV infection among injecting drug users in high-risk countries: an assessment of the evidence. Washington, DC: Institute of Medicine, 2007.
21. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction 2010; 105: 844-859.
22. Jones L, Pickering L, Sumnall H, McVeigh J, Bellis MA. A review of the effectiveness and cost-effectiveness of needle and syringe programmes for injecting drug users. June, 2008. http://www.nice. org.uk/nicemedia/pdf/ NSPRevieweffectivenesscosteffect ExecsummaryJune08.pdf (accessed May 18, 2010).
23. Weller SC, Davis-Beaty K. Condom effectiveness in reducing heterosexual HIV transmission. Cochrane Database Syst Rev 2002; 1: CD003255.
24. Galárraga O, Colchero MA, Wamai RG, Bertozzi SM. HIV prevention cost-effectiveness: a systematic review. BMC Public Health 2009; 9 (suppl 1): S5.
25. Gowing L, Farrell M, Bornemann R, Sullivan L, Ali R. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2008; 2: CD004145.
26. Faggiano F, Vigna-Taglianti F, Versino E, Lemma P. Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002208.
27. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; 1: CD002209.
28. Sullivan LE, Metzger DS, Fudala PJ, Fiellin DA. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 2005; 100: 150-158.
29. Lobmaier P, Kornør H, Kunøe N, Bjørndal A. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; 2: CD006140.
30. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2006; 1: CD001333.
31. Silva de Lima M, Lima Reisser AA, Soares BG, Farrell M. Antidepressants for cocaine dependence. Cochrane Database Syst Rev 2003; 2: CD002950.
32. Soares B, Lima Reisser AA, Farrell M, Silva de Lima M. Dopamine agonists for cocaine dependence. Cochrane Database Syst Rev 2003; 2: CD003352.
33. Minozzi S, Amato L, Davoli M, et al. Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev 2008; 2: CD006754.
34. Knapp WP, Soares BG, Farrell M, Silva de Lima M. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev 2007; 3: CD003023.
35. Shahmanesh M, Patel V, Mabey D, Cowan F. Effectiveness of interventions for the prevention of HIV and other sexually transmitted infections in female sex workers in resource poor setting: a systematic review. Trop Med Int Health 2008; 13: 659-679.
36. Manhart LE, Holmes KK. Randomized controlled trials of individual-level, population-level, and multilevel interventions for preventing sexually transmitted infections: what has worked? J Infect Dis 2005; 191 (suppl 1): 7-24.
37. Vickerman P, Terris-Prestholt F, Delany S, Kumaranayake L, Rees H, Watts C. Are targeted HIV prevention activities cost-effective in high prevalence settings? Results from a sexually transmitted infection treatment project for sex workers in Johannesburg, South Africa. Sex Transm Dis 2006; 33 (10 suppl): S122-32.
38. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23: 1397-1404.
39. Wood E, Kerr T, Marshall BDL, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009; 338: b1649.
40. Kerr T, Kimber J, DeBeck K, Wood E. The role of safer injection facilities in the response to HIV/AIDS among injection drug users. Curr HIV/AIDS Rep 2007; 4: 158-164.
41. Hedrich D. European report on drug consumption rooms. February, 2004. http://www.emcdda.europa.eu/attachements.cfm/att-2944-EN-consumption-rooms- report.pdf (accessed May 26, 2010).
42. Andresen MA, Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. Int J Drug Policy 2010; 21: 70-76.
43. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 2008; 179: 1105-1106.
44. WHO. Assessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Viet Nam: an application of selected human rights principles. 2009. http://www.who.int/hiv/topics/idu/drug-dependence/compulsory- treatment-wpro.pdf (accessed May 13, 2010).
45. Pearshouse R. Compulsory drug treatment in Thailand: observations on the Narcotic Addict Rehabilitation Act B.E. 2545 (2002). January, 2009. http://www.aidslaw.ca/publications/interfaces/downloadFile.php?ref=1429 (accessed May 18, 2010).
46. International Harm Reduction Development Program (Open Society Institute). Human rights abuses in the name of drug treatment: reports from the field. 2009. http://www.soros.org/initiatives/health/focus/ihrd/articles- publications/publications/treatmentabuse-20090318/treatmentabuse-20090309.pdf (accessed May 18, 2010).
47. Vietnam Department of General Social Evils Prevention, Constella Group, UK Department for International Development. Preliminary findings from an economic and public health analysis of institutional and community responses to injecting drug use and HIV/AIDS in Vietnam. Hanoi: Ministry of Labor Invalids and Social Affairs (MOLISA), 2008.
48. Kaplan EH. Needles that kill: modeling human immunodeficiency virus transmission via shared drug injection equipment in shooting galleries. Rev Infect Dis 1989; 11: 289-298.
49. Kaplan EH, Heimer R. A model-based estimate of HIV Infectivity via Needle Sharing. J Acquir Immune Defic Syndr 1992; 5: 1116-1118.
50. Advisory Council on the Misuse of Drugs. The primary prevention of hepatitis C among injecting drug users. February, 2009. http://www.hepctrust. org.uk/OneStopCMS/Core/CrawlerResourceServer. aspx?resource= a50a1f8cd13244b89e36cfdfbc7b354a&mode=link&gu id= fd3b10eb79d64f1c9c4c157706c22995 (accessed May 26, 2010).
51. Ksobiech K. A meta-analysis of needle sharing, lending, and borrowing behaviors of needle exchange program attenders. AIDS Educ Prev 2003; 15: 257-268.
52. Heimer R. Community coverage and HIV prevention: assessing metrics for estimating HIV incidence through syringe exchange. Int J Drug Policy 2008; 19 (suppl 1): S65-73.
53. Vickerman P, Hickman M, Rhodes T, Watts C. Model projections on the required coverage of syringe distribution to prevent HIV epidemics among injecting drug users. J Acquir Immune Defic Syndr 2006; 42: 355-361.
54. Bluthenthal RN, Ridgeway G, Schell T, Anderson R, Flynn NM, Kral AH. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction 2007; 102: 638-646.
55. Vickerman P, Miners A, Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: an economic modelling report. October, 2008. http://www.nice.org.uk/nicemedia/ live/12130/43370/43370.pdf (accessed May 27, 2010).
56. WHO. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. 2009. http://www.who.int/substance-abuse/publications/ Opioid-dependence-guidelines.pdf (accessed Feb 22, 2010).
57. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28: 321-329.
58. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2009; 3: CD002207.
59. WHO/UNODC/UNAIDS. Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper. 2004. http://www.unodc.org/docs/treatment/Brochure-E.pdf (accessed May 13, 2010).
60. Wong K-H, Lee S-S, Lim W-L, Low H-K. Adherence to methadone is associated with a lower level of HIV-related risk behaviors in drug users. J Subst Abuse Treat 2003; 24: 233-239.
61. van Griensvan F, Keawkungwal J, Tappero JW, et al. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand. AIDS 2004; 18: 295-301.
62. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2005; 2: CD003410.
63. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-218.
64. Amato L, Minozzi S, Davoli M, Vecchi S, Ferri M, Mayet S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev 2008; 4: CD005031.
65. Day E, Ison J, Strang J. Inpatient versus other settings for detoxification for opioid dependence. Cochrane Database Syst Rev 2005; 2: CD004580.
66. Meader N, Li R, Des Jarlais D, Pilling S. Psychosocial interventions for reducing injection and sexual risk behaviour for preventing HIV in drug users. Cochrane Database Syst Rev 2010; 1: CD007192.
67. Dolan K, Clement N, Rouen D, Rees V, Shearer J, Wodak A. Can drug injectors be encouraged to adopt non-injecting routes of administration (NIROA) for drugs? Drug Alcohol Rev 2004; 23: 281-286.
68. Hunt N, Griffiths P, Southwell M, Stillwell G, Strang J. Preventing and curtailing injecting drug use: a review of opportunities for developing and delivering 'route transition interventions'. Drug Alcohol Rev 1999; 18: 441-451.
69. UNODC Regional Centre for East Asia and the Pacific. HIV/AIDS and custodial settings in south east Asia: an exploratory review into the issue of HIV/AIDS and custodial settings in Cambodia, China, Lao PDR, Myanmar, Thailand and Viet Nam. 2006. http://www. aidslex.org/site-documents/PR-0043E.pdf (accessed May 13, 2010).
70. Human Rights Watch. Not enough graves: the war on drugs, HIV/AIDS, and violations of human rights. July 7, 2004. http://www.hrw.org/en/reports/2004/07/ 07/not-enough-graves?print (accessed May 18, 2010).
71. Jürgens R, Csete J, Amon JJ, Baral S, Beyrer C. People who use drugs, HIV, and human rights. Lancet 2010; published online July 20. DOI:10.1016/S0140-6736(10)60830-6.
72. Devaney M, Reid G, Baldwin S. Situational analysis of illicit drug issues and responses in the Asia-Pacific region. 2006. http://www. ancd.org.au/images/PDF/Researchpapers/rp12-asia-pacific.pdf (accessed May 25, 2010).
73. National Authority for Combating Drugs/UNODC. Report on illicit drug data and routine surveillance systems in Cambodia 2007. June, 2008. http://www.unodc.org/documents/eastasiaandpacific//Publications/Projects/ NACD-Annual-report2007.pdf (accessed May 18, 2010).
74. Zhao C, Liu Z, Zhao D, et al. Drug abuse in China. Ann N Y Acad Sci 2004; 1025: 439-445.
75. Jahani MR, Kheirandish P, Hosseini M, et al. HIV seroconversion among injection drug users in detention, Tehran, Iran. AIDS 2009; 23: 538-540.
76. Thomson N. Detention as treatment: detention of methamphetamine users in Cambodia, Laos and Thailand. March, 2010. http://www.soros.org/initiatives/ health/focus/ihrd/articles-publications/publications/detention-as-treatment- 20100301/Detention-as-Treatment-20100301.pdf (accessed May 27, 2010).
77. Taiwan Ministry of Education, Taiwan Ministry of Justice, Taiwan Ministry of Foreign Affairs, Taiwan Department of Health. Anti-drug report, 1st edn. Taipei: Ministry of Education, 2009.
78. UNDP. The European Union's Border Management Programme in Central Asia: country profile-Turkmenistan. New York: United Nations Development Programme, Sept 30, 2008.
79. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 2001; 357: 1397-1401.
80. Kelly JA, Murphy DA, Sikkema KJ, et al. Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities. Lancet 1997; 350: 1500-1505
81. WHO/UNODC. Guidance on testing and counselling for HIV in settings attended by people who inject drugs: improving access to treatment, care and prevention. 2009. http://www.wpro.who.int/NR/ rdonlyres/0B80B4CC-6484-4096-AA9E- 3C34BBCA3AAC/0/GuidanceonTCinIDUsettings-pagevicorrected.pdf (accessed May 18, 2010).
82. Rhodes T, Platt L, Maximova S, et al. Prevalence of HIV, hepatitis C and syphilis among injecting drug users in Russia: a multi-city study. Addiction 2006; 101: 252-266.
83. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330: 24-25.
84. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 (suppl 1): S11-19.
85. Vickerman P, Hickman M, Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007; 36: 396-405.
86. Vickerman P, Platt L, Hawkes S. Modelling the transmission of HIV and HCV amongst injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan. Sex Transm Infect 2009; 85 (suppl 2): ii23-30.
87. Van Den Berg C, Smit C, Van Brussel G, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007; 102: 1454-1462.
88. Des Jarlais D, Perlis T, Arasteh K, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health 2005; 95: 1439-1444.
89. Des Jarlais DC, Kling R, Hammett TM, et al. Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project. AIDS 2007; 21 (suppl 8): S109-14.
90. Wu Z, Luo W, Sullivan S, et al. Evaluation of a needle social marketing strategy to control HIV among injecting drug users in China. AIDS 2007; 21 (suppl 8): S115-22.
91. WHO. Consensus statement: addressing knowledge gaps in the public health approach to delivering antiretroviral therapy and care. Aug 4, 2008. http://www.who.int/hiv/pub/operational/consensus-statement-research-pha.pdf (accessed May 18, 2010).
92. Quinn TC, Wawer MJ, Sewankambo N, et al, for The Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000: 342: 921-929.
93. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS 2008; 22: 2179-2185.
94. Montaner JSG, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet 2006; 368: 531-536.
95. Young T, Arens FJ, Kennedy GE, Laurie JW, Rutherford GW. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev 2007; 1: CD002835.
96. Smith DK, Grohskopf LA, Black RJ, et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the US Department of Health and Human Services. MMWR Recomm Rep 2005; 54 (RR-2): 1-20.
97. Okwundu CI, Okoromah C. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2009; 1: CD007189.
98. National Centre in HIV Epidemiology and Clinical Research. Return on investment 2: evaluating the cost-effectiveness of needle and syringe programs in Australia 2009. http://www. health.gov.au/internet/main/publishing.nsf/ Content/C562D0E86 0733E9FCA257648000215C5/$File/return2.pdf (accessed May 25, 2010).
99. Guinness L, Vickerman P, Quayyum Z, et al. The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. Addiction 2010; 105: 319-328.
100. Kumaranayake L, Vickerman P, Walker D, et al. The cost-effectiveness of HIV preventive measures among injecting drug users in Svetlogorsk, Belarus. Addiction 2004; 99: 1565-1576.
101. Hall W, Doran C, Degenhardt L, Shepard D. Illicit opiate abuse. In: Jamison DT, Breman JG, Measham AR, et al, eds. Disease control priorities in developing countries, 2nd edn. April, 2006. http://files.dcp2.org/pdf/DCP/DCP48. pdf (accessed May 18, 2010).
102. Godfrey C, Stewart D, Gossop M. Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). Addiction 2004; 99: 697-707.
103. Gupta GR, Parkhurst JO, Ogden JA, Aggleton P, Mahal A. Structural approaches to HIV prevention. Lancet 2008; 372: 764-775.
104. Piot P, Bartos M, Larson H, Zewdie D, Mane P. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008; 372: 845-859.
105. Ball AL, Rana S, Dehne KL. HIV prevention among injecting drug users: responses in developing and transitional countries. Public Health Rep 1998; 113 (suppl 1): 170-181.
106. Kerr T, Wodak A, Elliott R, Montaner JS, Wood E. Opioid substitution and HIV/AIDS treatment and prevention. Lancet 2004; 364: 1918-1919.
107. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. Methadone maintenance and cessation of injecting drug user: results from the Amsterdam Cohort Study. Addiction 2000; 95: 591-600.
108. Sullivan LE, Fiellin DA. Buprenorphine: its role in preventing HIV transmission and improving the care of HIV-infected patients with opioid dependence. Clin Infect Dis 2005; 41: 891-896.
109. Lert F, Kazatchkine M. Antiretroviral HIV treatment and care for injecting drug users: an evidence-based overview. Int J Drug Policy 2007; 18: 255-261.
110. Malta M, Strathdee S, Magnanini M, Bastos F. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: A systematic review. Addiction 2008; 103: 1242-1257.
111. Palepu A, Tyndall MW, Joy R, et al. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend 2006; 84: 188-194.
112. Roux P, Carrieri M, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49: 1433-1440.
113. Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: A review of barriers and ways forward. Lancet 2010; published online July 20. DOI:10.1016/S0140- 6736(10)60832-X.
114. WHO/UNODC/UNAIDS. Technical guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users. Feb 6, 2009. http://www.who.int/hiv/pub/idu/idu-target-setting-guide.pdf (accessed May 18, 2010).
115. Cook C, Kanaef N. Global state of harm reduction 2008: mapping the response to drug related HIV and hepatitis C epidemics. May, 2008. http://www.ihra.net/Assets/1396/1/GSHRFullReport1. pdf (accessed May 18, 2010).
116. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Sept, 2009. http://www.who.int/hiv/pub/ 2009progressreport/en/index.html (accessed May 18, 2010).
117. Vickerman P, Watts CH. The impact of an HIV prevention intervention for injecting drug users in Svetlogorsk, Belarus: model predictions. Int J Drug Policy 2002; 13: 149-164.
118. Blankenship K, Friedman S, Dworkin S, Mantell J. Structural interventions: concepts, challenges and opportunities for research. J Urban Health 2006; 83: 59-72.
119. Rhodes T, Simic M. Transition and the HIV risk environment. BMJ 2005; 331: 220-223.
120. Dolan K, Kite B, Black E, Aceijas C, Stimson GV, for the Reference Group on HIV/AIDS Prevention and Care among Injecting Drug Users in Developing and Transitional Countries. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007; 7: 32-41.
121. Jürgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis 2009; 9: 57-66.
122. Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction 2010; 105: 216-223.
123. MSIC Evaluation Committee. Final report of the evaluation of the Sydney Medically Supervised Injecting Centre. 2003. http://www. druginfo.nsw.gov.au/- data/page/1229/NDARC-final-evaluation-report4.pdf (accessed May 18, 2010).
124. Kimber J, Palmateer N, Hutchinson S, Hickman M, Goldberg D, Rhodes T. Harm reduction among injecting drug users: evidence of effectiveness (chapter 5). In: Rhodes T, Hedrich D, eds. Harm reduction: evidence, impacts and challenges. April, 2010. http://www.emcdda.europa.eu/publications/monographs/ harm-reduction (accessed May 18, 2010).
125. Campbell R, Starkey F, Holliday J, et al. An informal school-based peer-led intervention for smoking prevention in adolescence (ASSIST): a cluster randomised trial. Lancet 2008; 371: 1595-1602.
126. Hammett T, Kling R, Johnston P, et al. Patterns of HIV prevalence and HIV risk behaviors among injection drug users prior to and 24 months following implementation of cross-border HIV prevention interventions in northern Vietnam and southern China. AIDS Educ Prev 2006; 18: 97-115.
127. Weeks MR, Dickson-Gomez J, Mosack KE, Convey M, Martinez M, Clair S. The risk avoidance partnership: training active drug users as peer health advocates. J Drug Issues 2006; 36: 541-570.
128. Weeks MR, Convey M, Dickson-Gomez J, et al. Changing drug users' risk environments: peer health advocates as multi-level community change agents. Am J Community Psychol 2009; 43: 330-344.
129. Weeks MR, Li J, Dickson-Gomez J, et al. Outcomes of a peer HIV prevention program with injection drug and crack users: the Risk Avoidance Partnership. Subst Use Misuse 2009; 44: 253-281.
130. Jana S, Bandyopadhyay N, Saha A, Dutta MK. Creating an enabling environment: lessons learnt from the Sonagachi Project, India. In: Research for sex work 2: appropriate health services. Amsterdam: VU University Medical Center, 1999: 22-24.
131. Pronyk PM, Hargreaves JR, Kim JC, et al. Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial. Lancet 2006; 368: 1973-1983.
132. Dworkin S, Blankenship K. Microfinance and HIV/AIDS prevention: assessing its promise and limitations. AIDS Behav 2009; 13: 462-469.
133. Aidala A, Cross J, Stall R, Harre D, Sumartojo E. Housing status and HIV risk behaviors: implications for prevention and policy. AIDS Behav 2005; 9: 251-265.
134. Taussig JA, Weinstein B, Burris S, Jones TS. Syringe laws and pharmacy regulations are structural constraints on HIV prevention in the US. AIDS 2000; 14 (suppl 1): S47-51.
135. Fuller C, Ahern J, Vadnai L, et al. Impact of increased syringe access: preliminary findings on injection drug user syringe source, disposal, and pharmacy sales in Harlem, New York. J Am Pharm Assoc (Wash) 2002; 42 (6 suppl 2): S77-82.
136. Rhodes T, Mikhailova L, Sarang A, et al. Situational factors influencing drug injecting, risk reduction and syringe exchange in Togliatti City, Russian Federation: a qualitative study of micro risk environment. Soc Sci Med 2003; 57: 39-54.
137. Cooper H, Moore L, Gruskin S, Krieger N. The impact of a police drug crackdown on drug injectors' ability to practice harm reduction: a qualitative study. Soc Sci Med 2005; 61: 673-684.
138. Davis C, Burris S, Kraut-Becher J, Lynch K, Metzger D. Effects of an intensive street-level police intervention on syringe exchange program use in Philadelphia, PA. Am J Public Health 2005; 95: 233-236.
139. Pollini R, Brouwer K, Lozada R, et al. Syringe possession arrests are associated with receptive syringe sharing in two Mexico-US border cities. Addiction 2008; 103: 101-108.
140. Friedman SR, Cooper H, Tempalski B, et al. Relationships of deterrence and law enforcement to drug-related harms among drug injectors in US metropolitan areas. AIDS 2006; 20: 93-99.
141. Friedman S, de Jong W, Rossi D, et al. Harm reduction theory: users' culture, micro-social indigenous harm reduction, and the self-organization and outside-organizing of users' groups. Int J Drug Policy 2007; 18: 107-117.
142. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review. BMC Med Res Methodol 2006; 6: 54.
143. Hope VD, Hickman M, Ngui SL, et al. Measuring the incidence, prevalence, and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat (published online April 27, 2010). DOI:10.1111/j.1365-2893.2010.01297.x.
144. Janssen R, Satten G, Stramer S, et al. New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998; 280: 42-48.
145. Kroll C, de Lay P. Letter from UNODC and UNAIDS Secretariat. Aug 21, 2009. http://www.idpc.net/alerts/unaids-unodc-joint-letterharm- reduction (accessed May 18, 2010).
146. UN. The universal declaration of human rights. Dec 10, 1948. http://www.un.org/en/documents/udhr/(accessed Feb 22, 2010).
147. Tan-Torres Edejer T, Baltussen R, Adam T, et al. Making choices in health: WHO guide to cost-effectiveness analysis. 2003. http://www. who.int/choice/publications/p-2003-generalised-cea.pdf (accessed Feb 22, 2010).
148. Stimson GV, Cook C, Bridge J, Rio-Navarro J, Lines R, Barrett D. Three cents a day is not enough: resourcing HIV-related harm reduction on a global basis. 2010. http://www.ihra.net/Assets/2518/1/IHRA-3CentsReport-Web.pdf (accessed May 18, 2010).
149. UNAIDS. Financial resources required to achieve universal access to HIV prevention, treatment, care and support. Sept 26, 2007. http://data.unaids.org/ pub/Report/2007/JC1678-Fin-Res-Req-en.pdf (accessed May 18, 2010).
150. Kates J, Lief E, Avila C. Financing the response to AIDS in low- and middle-income countries: international assistance from the G8, European Commission and other donor Governments in 2008. July, 2009. http://www. unaidscaribbean.org/uploads/group%20 of %20eight%20funding%20for%20hiv.pdf (accessed Feb 25, 2010).